Patiromer - Relypsa

Drug Profile

Patiromer - Relypsa

Alternative Names: ILY-105; Patiromer calcium; Patiromer for Oral Suspension; Patiromer FOS; Patiromer sorbitex calcium; RLY-105; RLY-5016; RLY-5016S; RLY5016 for Oral Suspension; Veltassa

Latest Information Update: 20 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Relypsa
  • Developer Relypsa; Vifor Fresenius Medical Care Renal Pharma
  • Class Polymers
  • Mechanism of Action Potassium binding modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hyperkalaemia

Most Recent Events

  • 11 Apr 2018 Pooled efficacy and adverse events data from a OPAL-HK, AMETHYST-DN and TOURMALINE trials in Hyperkalaemia released by Relypsa
  • 27 Mar 2018 Patiromer licensed to Zeria in Japan
  • 15 Mar 2018 Vifor Pharma plans to a full launch of patriomer in Europe 2018 and 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top